These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9863218)

  • 1. [Analysis of population pharmacokinetics with NONMEM in clinical patients treated with amikacin by intravenous infusion].
    Chu XM; Rui JZ; Zhou YG; Dai YJ; Cai WM; Ling SS
    Yao Xue Xue Bao; 1996; 31(12):881-5. PubMed ID: 9863218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
    Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
    Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn.
    Yang RH; Rong XZ; Hua R; Zhang T
    Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin.
    Halacova M; Kotaska K; Kukacka J; Vavrova V; Kuzelova M; Ticha J; Prusa R
    J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetics of amikacin in the subeschar tissue fluid following severe burns].
    Yang RH; Rong XZ; Zhang T; Hua R
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Feb; 27(2):172-4. PubMed ID: 17355928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Assessment of pharmacokinetic parameters of amikacin in a group of neutropenic patients in onco-hematology].
    Pivot-Dumarest C; Deweerdt C; Troncy J; Sorensen P; Roux D; Maire P
    Pathol Biol (Paris); 1996 Apr; 44(4):299-305. PubMed ID: 8763595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen.
    Conil JM; Georges B; Breden A; Segonds C; Lavit M; Seguin T; Coley N; Samii K; Chabanon G; Houin G; Saivin S
    Int J Antimicrob Agents; 2006 Sep; 28(3):226-30. PubMed ID: 16908121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Influence of total parenteral nutrition on amikacin pharmacokinetics].
    Cai WM; Yu GH; Chen G
    Zhongguo Yao Li Xue Bao; 1989 Sep; 10(5):428-31. PubMed ID: 2515746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of population pharmacokinetics of cyclosporin A in renal transplantation patients with NONMEM].
    Rui JZ; Zhuo HT; Jiang GH; Chen G
    Yao Xue Xue Bao; 1995; 30(4):241-7. PubMed ID: 7660791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic analysis of amikacin and validation on neonates using Monte Carlo method.
    Wang J; Liang WQ; Wu JJ; Pan CM
    Acta Pharmacol Sin; 2000 Oct; 21(10):954-60. PubMed ID: 11501052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
    Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
    J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of gentamicin in premature newborns.
    García B; Barcia E; Pérez F; Molina IT
    J Antimicrob Chemother; 2006 Aug; 58(2):372-9. PubMed ID: 16782742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type.
    Yamamoto M; Kuzuya T; Baba H; Yamada K; Nabeshima T
    J Clin Pharm Ther; 2009 Aug; 34(4):473-83. PubMed ID: 19583681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin.
    Delattre IK; Musuamba FT; Jacqmin P; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq P
    Clin Biochem; 2012 Jul; 45(10-11):780-6. PubMed ID: 22503878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
    Mar Fernández de Gatta MD; Victoria Calvo M; Ardanuy R; Domínguez-Gil A; Lanao JM; Moreno SR
    J Pharm Pharmacol; 2009 Jun; 61(6):759-66. PubMed ID: 19505366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin.
    Hermida J; Tutor JC
    Ther Drug Monit; 2006 Jun; 28(3):326-31. PubMed ID: 16778715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Can we use a Bayesian method to build a pharmacokinetic population in two steps?].
    Cabelguenne D; Bleyzac N; Pivot C; Maire P
    Therapie; 2000; 55(2):277-82. PubMed ID: 10967700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition of single-dose intravenously administered amikacin in emus (Dromaius novaehollandiae).
    Helmick KE; Boothe DM; Jensen JM
    J Zoo Wildl Med; 1997 Mar; 28(1):49-54. PubMed ID: 9226616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Amikacin pharmacokinetics in adults: a variability that question the dose calculation based on weight].
    Bourguignon L; Goutelle S; Gérard C; Guillermet A; Burdin de Saint Martin J; Maire P; Ducher M
    Therapie; 2009; 64(1):47-53. PubMed ID: 19463252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of a single daily intramuscular dose of gentamicin in children with severe malnutrition.
    Seaton C; Ignas J; Muchohi S; Kokwaro G; Maitland K; Thomson AH
    J Antimicrob Chemother; 2007 Apr; 59(4):681-9. PubMed ID: 17347177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.